SOPHiA Genetics签署了两项协议，以推进人工智能在精准医疗中的应用

2025-11-11 23:46

SOPHiA Genetics (SOPH) has signed partnerships with Complete Genomics and Element Biosciences to integrate the former's AI-powered analytics platforms with Complete's and Element's own sequencing platforms.
Both deals involve the MSK-ACCESS and MSK-IMPACT cancer genomic profiling tests. The tests utilize the SOPHiA DDM platform to analyze complex genomic and multimodal data to generate real-time insights.
Complete Genomics' DNBSEQ-T1+ sequencing platform with be integrated with the two MSK tests, while Element Biosciences' AVITI24 5D multiomic and AVITI sequencing systems will be integrated.
"By combining MSK's rigorously validated assays, SOPHiA Genetics' robust analytics, and our sequencing technology, we are enabling decentralized labs to deliver faster, more accurate, and more affordable insights to clinicians and researchers," Complete Genetics VP, Product and Marketing Rob Tarbox said in a statement.

More on SOPHiA Genetics